Scroll through TikTok or Instagram today and it does not take long before you see it: someone injecting a clear liquid, then telling millions of viewers it changed their body, boosted recovery, or improved their skin.
That substance is often referred to as a peptide. On paper, peptides are short chains of amino acids that help regulate biological processes in the body. In medicine, some peptide-based drugs are legitimate and strictly regulated, including GLP-1 medications such as semaglutide used for diabetes and weight loss.
But alongside approved therapies, a far less controlled market has grown online. Many of the peptides being promoted across social media are unapproved, unverified, and in some cases not what they claim to be.
A market hiding in plain sight
Recent research suggests peptide-related content is no longer a niche corner of the internet. More than 130,000 Instagram posts and over 230 million TikTok views are linked to peptide discussions, according to recent estimates.
What makes this different from traditional underground drug markets is visibility. The content is not hidden. It is algorithmically recommended, shared, and monetised on mainstream platforms used daily by millions.
At a recent public health roundtable at the University of Queensland, clinicians, researchers, and industry stakeholders highlighted a growing concern: peptides are now one of the easiest substances to discover online, and one of the hardest to regulate.
The bigger issue, they argue, is not just access. It is misunderstanding.
Many users do not see themselves as “drug users” at all. Instead, peptides are framed as wellness tools, fitness enhancers, or recovery aids, which can make people less likely to seek medical help when something goes wrong.
What is actually in these products?
Outside regulated pharmacies, the answer is often unclear.
Independent laboratory testing of peptide products purchased from unregulated markets has revealed wide inconsistencies. Some products labelled as experimental weight-loss peptides contained incorrect dosages ranging from half to nearly double the stated amount. Others contained entirely different substances or no active ingredient at all.
That uncertainty is not just a quality issue. It is a safety issue.
Even small dosing errors in injectable compounds can lead to severe side effects, including gastrointestinal distress, hormonal disruption, and potentially life-threatening complications. In one recent case reported by Australia’s Therapeutic Goods Administration, the use of an unapproved peptide was linked to a severe adverse reaction involving a torn oesophagus following uncontrolled vomiting.
Social media as the new distribution channel
Platforms typically respond to peptide-related content by removing flagged posts or banning accounts. But researchers say this approach is reactive, not preventive.
New accounts and listings often appear as quickly as others are removed, creating a cycle of enforcement that struggles to keep pace with demand.
This pattern mirrors earlier waves of online health-risk content, including illicit vaping promotion. Studies have shown that vape-related videos often emphasise lifestyle appeal and entertainment while downplaying or omitting health risks entirely.
In some cases, illicit vaping products have even been found to contain unexpected substances, including sedatives, highlighting how opaque unregulated supply chains can become.
A growing call for platform responsibility
Public health experts argue that social media companies need to move beyond content removal and toward prevention.
One proposed solution is proactive health education built directly into platforms. For example, when users search for peptide-related terms, they could be shown clear, evidence-based information explaining what peptides are, what is known and unknown about their safety, and where to seek medical guidance.
Similar interventions already exist for topics like self-harm or suicide-related content, where platforms redirect users toward support resources.
Another recommendation is real-time data sharing between platforms, regulators, and independent researchers. At present, there is no consistent system for tracking how peptide-related content spreads, which compounds are being discussed, or where potential harm is emerging.
Without that visibility, experts warn, regulation will always lag behind the market.
The core problem
The debate is not whether platforms caused the rise of peptide interest. It is that they now sit at the centre of how that interest spreads.
For a teenager scrolling through a feed, peptide content can look indistinguishable from fitness advice or wellness inspiration. But unlike traditional health education, the information is often unverified, commercially driven, and disconnected from clinical oversight.
And that gap, researchers argue, is where the risk is growing fastest.